Mova/Sandoz Rebut King’s Levothyroxine Lawsuit, Cite Reliance On Own Equivalence Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Certification to a King patent listed in the “Orange Book” was unnecessary because Mova’s sNDA approval was based on its own bioequivalence data and FDA advised the company it did not need to certify to the patent, Mova says.
You may also be interested in...
King Sues FDA Over Levoxyl Bioequivalence Claims For Levo-T, Unithroid
The agency should not have accepted supplemental NDAs that lacked Paragraph IV certifications to a King patent, the company says. King is asking the court to revoke approvals for Jerome Stevens and Mova/Sandoz and to enjoin FDA from approving other 505(b)(2) supplements claiming equivalence to Levoxyl.
Bristol To Name New R&D Head Shortly
Senior VP-Global Clinical & Pharmaceutical Development Elliott Sigal is acting president of Bristol-Myers Squibb’s research institute following the death of James Palmer.
Aranesp Performance Strong Heading Into "Transition" Time, Amgen Says
The company is talking with oncologists about Aranesp ahead of a switch in Medicare reimbursement in January 2005. U.S. sales for the red blood cell product were up 32% in the third quarter.